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Dear Editor,
“Histiocytic sarcoma” is a rare haematological neoplasm
with immunohistochemical and morphological diagnostic
criteria per exclusionem. In this case report, our patient
illustrates that this rare tumour with its unique location and
diagnostic morphologic criteria is sensitive to a combina-
tion of anthracycline-based chemotherapy and radiotherapy,
resulting in complete response for 2 years.
A 64-year-old Caucasian woman presented with an
asymptomatic, gradually enlarging neck mass at the
Outpatient Department of Internal Medicine. Laboratory
results showed subclinical hypothyroidism. Thyroid scin-
tigraphy revealed a cold nodule in the left lower thyroid
lobe. Results of aspiration cytology were compatible with
an infected cyst. Based on the presence of a goitre,
subclinical hypothyroidism and auto-antithyroid peroxidase
antibodies >600 kU/L, a diagnosis of Hashimoto’s thyroid-
itis was suspected and treated with levothyroxin. Five
months later she developed neck pain. Pre-operative tru-cut
biopsy showed a cell-rich tumour proliferation, possibly
histiocytic. Further histological biopsies by open surgery
incision showed diffuse proliferation of cells made up of
large, bizarre, lobulated, vesicular nuclei with one or more
conspicuous nucleoli and ample eosinophilic cytoplasm.
Between these cells scattered plasma cells and occasional
lymphocytes were seen. No thyroid tissue was present.
Immunohistochemical staining revealed strong cytoplasmic
expression for CD68 (clones KP-1 and PGM-1) (Fig. 1),
lysozym and α1-antitrypsin, whereas lymphoid and mye-
loid markers (CD43, myeloperoxidase) were all negative as
well as keratins, thyreoglobulin, calcitonin and S100.
Melan-A, thyrosinase and HMB45 (melanocytic markers)
were also negative, excluding the differential diagnosis of
metastatic malignant melanoma. Molecular analysis of T
cell receptor (TcR) with polymerase chain reaction revealed
an unusual, but consistent pattern of TcR rearrangement,
not supporting a malignant process of lymphoid origin. On
morphological grounds, diagnosis of histiocytic sarcoma
was favoured over anaplastic lymphoma and anaplastic
thyroid carcinoma as the cells lacked expression of CD30,
keratins, thyreoglobulin and calcitonin.
Computed tomography (CT) and 18F-fluorodeoxyglu-
cose-positron emission tomography (PET) scanning
showed a mass in the left thyroid lobe without metastases.
A bone marrow biopsy showed normal histology. Chemo-
therapy (cyclophosphamide 750 mg/m
2, doxorubicin
50 mg/m
2 and vincristine 2 mg on day 1 with prednisolon
60 mg/m
2 on day 1 through 5) was administered intrave-
nously every 3 weeks for three cycles. This resulted in
partial response. Apart from alopecia, no other side effects
were noticed. After chemotherapy, radiotherapy in a dose of
40 Gy was given to the thyroid and left side of the neck.
This resulted in a complete remission on staging with PET
scan and CT scan after completion of radiotherapy, which
persists for 2 years.
Histiocytic sarcoma is an extremely rare, malignant
proliferation of cells showing morphologic and immuno-
phenotypic features similar to those of histiocytes [1].
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e-mail: f.devos@erasmusmc.nlOriginally, the diagnosis of histiocytic lymphoma has been
made often, but further research revealed that most of such
cases represented tumours of lymphoid origin. Median age
of diagnosis is 46 years with a male predominance. First
presentation occurs in lymph nodes (in one third of all
cases), in the skin (1/3) and in extranodal sites, mostly
intestinal tract (1/3) with advanced disease stage [1].
Arising from phagocytes and related accessory cells with
presentation of antigens to lymphocytes, pathological
interpretation of lineage distinction can be difficult due to
poor differentiation of tumour cells [1–4]. Diagnosis is
based on histologic and immunohistochemical criteria,
ruling out epithelial, melanocytic, myeloid and lymphoid
origin. In our case, morphology showed histiocytic tumour
proliferation with immunophenotypic positivity for CD68,
lysozym and α1-antitrypsin without B-cell, T-cell, melano-
cytic and myeloid markers. Generally, the response is poor
due to the aggressive nature with high proliferative rate and
extranodal spread [1]. Primary treatment consists of radical
surgery with wide surgical margins, frequently combined
with elective radiotherapy. With no evidence-based data,
several chemotherapeutic schemes have been added to
surgery and radiotherapy, primarily for local control of the
disease. Recently, allogeneic haematopoietic stem cell
transplantation and thalidomide showed some response
[5]. The sequence of therapy modalities still needs to be
clarified. We preferred a neoadjuvant combination of
cyclophosphamide, doxorubicin and vincristine and radio-
therapy, resulting in complete response for 2 years.
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